Related Experiment Video
Updated: Sep 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine
Fausto Baldanti1, Stefania Paolucci, Giovanni Maga
1Servizio di Virologia, IRCCS Policlinico San Matteo, Pavia, Italy.
Abstract:
Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Viral Mutations
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Retroviruses
Retrovirus Life Cycles

